Bioqual Inc

Bioqual Inc has a strong liquidity position, with $17.85 million in cash and equivalents and a current ratio of 3.72, indicating the company can easily cover its short-term liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage risk. Free cash flow for the latest period was $635,840, and operating cash flow was $2.94 million, indicating positive cash generation despite a net loss. Profitability metrics show a challenging performance, with a return on equity of -2.9% and a return on assets of -1.84%, both below the industry median for Biotechnology & Medical Research firms. The company reported a net loss of $1.05 million and an operating loss of $1.90 million, indicating that it is not currently generating sufficient revenue to cover its operating costs. Gross profit was $4.42 million, but this was insufficient to offset operating expenses. The company's revenue is concentrated in a single business line, contract research services, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases exposure to sector-specific risks, such as regulatory changes or shifts in research funding. No material revenue concentration by geography is disclosed, but the absence of geographic breakdown suggests potential overreliance on a single market or client base. Outlook for the current fiscal year is mixed, with no significant revenue growth expected based on the latest financial data. The company's revenue of $48.87 million is flat compared to prior periods, and no material growth drivers are disclosed in the latest filings. The absence of capital expenditures and no long-term debt suggests the company is not currently investing in expansion or new facilities, which may limit future growth potential. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no long-term debt and a strong cash position, reducing financial leverage risk. However, the net loss and negative return on equity suggest operational inefficiencies or cost overruns that could impact future performance. No dilution risk is currently present, as shares outstanding have not changed between basic and diluted counts. Recent events include the disclosure of a net loss and operating loss in the latest financial snapshot, with no material changes in capital structure or significant transactions reported. The company's cash position remains strong, and no new debt or equity issuance is disclosed in the latest data. No recent regulatory or legal events are reported in the available data.